FACTORS OF OSTEOPOROSIS IN PATIENTS WITH CORONARY HEART DISEASE IN COMBINATION WITH RHEUMATOID ARTHRITIS
Keywords:
Keywords: osteoporosis, coronary heart disease, rheumatoid arthritis, risk factors, cardiovascular diseases, glucocorticosteroids, bone mineral density.Abstract
ABSTRACT
Rheumatoid arthritis is a systemic disease of unclear etiology with autoimmune
pathogenesis, which is characterized by chronic erosive polyarthritis. In some patients
with rheumatoid arthritis, there is a discrepancy between the processes of bone
resorption and bone formation, which is the cause of secondary metabolic osteopathies.
Such a complication of rheumatoid arthritis with a change in the quality of bone tissue
is osteoporosis. Coronary heart disease in combination with rheumatoid arthritis
exacerbates risk factors leading to a decrease in bone density and an increased risk of
fractures in osteoporosis, which determines the unfavorable course and significantly
worsens the prognosis of the disease. Currently, a number of studies have revealed an
association between an increased risk of osteoporosis (in patients with coronary heart
disease in combination with rheumatoid arthritis) and the following factors: low
mineral bone density, female gender, age over 65 years, early menopause, weight less
than 57 kg, family history of osteoporosis, previous fractures, long-term rheumatoid
arthritis and irrational glucocorticosteroid therapy. This article presents the results of
an analysis of the factors leading to the development of osteoporosis in patients with
coronary heart disease in combination with rheumatoid arthritis who are undergoing
inpatient treatment in the rheumatology department.
References
1. Хамраева, Н. А., Султонов, И. И., & Хасанов, Ф. Ш. У. (2019). Кожные
проявления у больных системной красной волчанкой. Вопросы науки и
образования, (28 (77)), 128-131.
2. Ziyadullaev, S. K., Sultonov, I. I., Dushanova, G. A., & Akbarovna, K. S. (2021).
The Effectiveness Of Pharmacotherapy For Dmards With Ra Depending On The
C3435t Polymorphism Of The Mdr1 Gene. Int. J. of Aquatic Science, 12(3), 2908-
2916.
3. Sultonov, I. I., Kh, Z. S., Ruzybakieva, M. R., Kireev, V. V., Aripova, T. U., &
Suyarov, A. A. (2021). Pharmacogenetic Aspects of Drug Resistance in
Rheumatoid Arthritis. Annals of the Romanian Society for Cell Biology, 4147-4150.
4. Kireev, V. V., & Sultonov, I. I. (2021). Genetic Engineered Preparations-An
Innovative Approach in the Treatment of Rheumatoid Arthritis. Annals of the
Romanian Society for Cell Biology, 4114-4119.
5. Hamraeva, N. A., Sultonov, I. I., & Hasanov, F. S. (2020). Systemic lupus
erythematosus treatment strategy. Journal of Critical Reviews, 7(9), 269-270.
6. Тоиров, А. Э., Султонов, И. И., & Тоиров, Э. С. (2020). ЗНАЧЕНИЕ
ДИСФУНКЦИИ ПОЧЕК У БОЛЬНЫХ ОСТРЫМ ИНФАРКТОМ
МИОКАРДА НА ФОНЕ САХАРНОГО ДИАБЕТА 2-ГО ТИПА. Вестник
науки и образования, (9-3 (87)), 86-91.
7. Иргашева, У. З., Султонов, И. И., & Тоиров, Д. Р. (2013). Признаки дебюта
системной красной волчанки. Академический журнал Западной Сибири, 9(1),
15-15.
8. Нурматова, Л., Султонов, И., & Тоиров, Э. (2011). Эффективность препаратов
пищеварительной активности в комплексном лечении больных хроническим
гепатитом. Журнал проблемы биологии и медицины, (3 (66)), 107-110.
9. Sultonov, I. I., Khamrayev, X. X., & Xasanov, F. SYSTEMIC LUPUS
ERYTHEMATOSUS AND CARDIOVASCULAR PATHOLOGY: WHERE WE
AT?.
10. Sultonov, I. I., Xasanov, F. S., Eshmuratov, S., Uralov, R. S., Shukurova, D., &
Ziyadullayev, S. X. Predictors of Systemic Lupus Erythematosus: A Case-control
Study. International journal of health sciences, 6(S10), 175-182.
11. Khusainova, M. A., Vakhidov, J. J., Khayitov, S. M., & Mamadiyorova, M. M.
(2023). Cardiac arrhythmias in patients with rheumatoid arthritis. Science and
Education, 4(2), 130-137.
12. Khusainova, M. A. (2023). Comorbidity thyrotoxicosis with coronary heart
disease. Science and Education, 4(5), 205-213.
13. Khusainova, M. A., Toirov, D. R., Khaydarov, S. N., & Kamolova, D. D. (2023).
MORPHOFUNCTIONAL PARAMETERS OF THE HEART IN WOMEN
SUFFERING FROM ESSENTIAL ARTERIAL HYPERTENSION IN POSTMENOPAUSE AND ON THE BACKGROUND OF
TREATMENT. Oriental renaissance: Innovative, educational, natural and social
sciences, 3(1), 322-330.
14. Djamshedovna, K. D., Alisherovna, K. M., Xudoyberdiyevich, G. X., &
Rustamovich, T. D. (2023). EFFECTIVENESS OF ANTIHYPERTENSIVE
THERAPY IN PREGNANT WOMEN. Spectrum Journal of Innovation, Reforms
and Development, 12, 137-144.
15. Alisherovna, K. M., Erkinovna, K. Z., Djamshedovna, K. D., & Nizamitdinovich,
K. S. (2023). QUALITY OF LIFE PATIENTS WITH
OSTEOARTHRITIS. Journal of new century innovations, 36(1), 164-175.
16. Djamshedovna, K. D., & Alisherovna, K. M. (2024). CHANGES IN SOME
SYSTEM INDICATORS IN PREGNANT WOMEN WITH GESTOSIS. Spectrum
Journal of Innovation, Reforms and Development, 25, 111-115.
17. Jamshedovna, K. D., Alisherovna, K. M., Erkinovna, K. Z., & Davranovna, M. K.
(2022). LEFT VENTRICULAR SYSTOLIC DYSFUNCTION IN PREGNANT
WOMEN WITH PRE-ECLAMPSIA WITHOUT PROTEINURIA. Spectrum
Journal of Innovation, Reforms and Development, 10, 135-140.
18. Alisherovna, K. M., Djamshedovna, K. D., Totlibayevich, Y. S., & Boymamatovna,
E. F. (2022). The Effectiveness of the Original Drug Trimetazidine MV in Patients
with Stable Ischemic Heart Disease and Persistent Angina Attacks Against the
Background of the Use of Trimetazidine Generics. Miasto Przyszłości, 30, 235-238.
19. Alisherovna, K. M., & Djamshedovna, K. D. (2024). AFTER COVID-19
QUALITY OF LIFE. Spectrum Journal of Innovation, Reforms and
Development, 25, 103-110.
20. Alisherovna, K. M., Jamshedovna, K. D., Totlibayevich, Y. S., &
Xudoyberdiyevich, G. X. (2022). FEATURES OF THE QUALITY OF LIFE OF
PATIENTS WITH CHRONIC RENAL FAILURE IN THE TREATMENT OF
HEMODIALYSIS. Spectrum Journal of Innovation, Reforms and Development, 7,
76-81.
21. Erkinovna, K. Z., Alisherovna, K. M., Bakhtiyorovich, U. J., & Djamshedovna, K.
D. (2023). METABOLIC SYNDROME IN RHEUMATOID ARTHRITIS. Journal
of new century innovations, 38(2), 203-211.
22. Islomovich, S. I. (2024). GENDER CHARACTERISTICS OF THE CURRENT
RHEUMATOID ARTHRITIS. International journal of medical sciences, 4(10), 3-
8.
23. Alisherovna, K. M., Ismatullayevich, M. A., & Nuriddinovna, E. N. (2024).
FEATURES OF HEART FAILURE IN PATIENTS WITH CORONARY HEART
DISEASE AND THYROTOXICOSIS. Ta'lim innovatsiyasi va
integratsiyasi, 19(4), 52-61.
24. Alisherovna, K. M., Yaxshiboyevich, U. M. R., & Yigitaliyevich, B. A. (2024).
EVALUATION OF A NATRIURETIC PEPTIDE TO OPTIMIZE THE
MANAGEMENT OF COMORBID PATIENTS WITH THYROTOXICOSIS
AND HEART FAILURE. Ta'lim innovatsiyasi va integratsiyasi, 19(4), 62-70.
25. Alisherovna, K. M., Mansurovna, M. D., Erkinovna, N. D., Farxodovna, X. R.,
Toxirovna, M. M., Tolibovna, R. D., & Yorkinovna, E. N. (2024). ARTERIAL
HYPERTENSION AND THYROID STATUS IN PATIENTS OF DIFFERENT
AGES. Ta'lim innovatsiyasi va integratsiyasi, 19(4), 122-129.
26. Alisherovna, K. M., Erkinovna, S. D., Duskobilovich, B. S., & Samandarovich, T.
H. (2024). ARTERIAL HYPERTENSION IN THYROTOXICOSIS AND
REMODELING OF THE LEFT VENTRICLE OF THE HEART. Ta'lim
innovatsiyasi va integratsiyasi, 19(4), 114-121.
27. Alisherovna, K. M., Erkinovna, S. D., Yazdonkulovna, X. M., & Zafarovna, C. M.
M. (2024). ATRIAL FIBRILLATION IN THYROTOXICOSIS–
DETERMINANTS OF DEVELOPMENT AND CONSERVATION. Ta'lim
innovatsiyasi va integratsiyasi, 19(4), 103-113.
28. Alisherovna, K. M., Habibulloyevna, I. M., & Voxidovna, R. F. (2024).
STRUCTURAL AND FUNCTIONAL FEATURES OF THE LEFT VENTRICLE
IN PATIENTS WITH HEART FAILUREIN ISCHEMIC HEART DISEASE AND
THYROTOXICOSIS. Ta'lim innovatsiyasi va integratsiyasi, 19(4), 71-81.
29. Davranovna, M. K. D. K., Alisherovna, K. M., & Erkinovna, K. Z. (2024).
CARDIAC ARRHYTHMIAS IN PATIENTS WITH RHEUMATOID
ARTHRITIS. Spectrum Journal of Innovation, Reforms and Development, 26, 65-
71.
30. Alisherovna, K. M., Kairatovna, R. A., Umirovna, I. S., & Oybekovich, T. M.
(2023). CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND
ANEMIA. Spectrum Journal of Innovation, Reforms and Development, 21, 140-
147.
